본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The Journal of antimicrobial chemotherapy v.72 no.2, 2017년, pp.496 - 503   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load

Gonzalez-Serna, Alejandro (BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada ); Glas, Arie C. ( Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands ); Brumme, C. J. ( BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada ); Poon, Art F. Y. ( BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada ); Nohpal De La Rosa, Adriana ( BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada ); Mudrikova, Tania ( Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands ); Dias Lima, Viviane ( BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada ); Wensing, Annemarie M. J. ( Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands ); Harrigan, Richard ( BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada );
  • 초록  

    Objectives: HIV drug resistance, measured by the genotypic susceptibility score (GSS), has a deleterious effect on the virological outcome of HIV-1-infected patients. However, it is not known if GSS retains any predictive value for CD4 recovery in patients with suppressed viral load. Methods: Four hundred and six patients on virological failure (>500 copies/mL) with GSS   <6 months prior to switch therapy who achieved undetectable plasma viral load (<50 copies/mL) within 1 year, remained undetectable >1 year on an unchanged regimen and had CD4 data available during entire follow-up were included. Adjusted and unadjusted analyses of all characteristics at switch related to CD4 recovery were made for three time frames: (i) ‘switch–suppression’; (ii) ‘suppression–1 year’; and (iii) ‘switch–1 year’. Results: Higher GSS was associated with a greater CD4 recovery between ‘switch’ and ‘1 year’ in the unadjusted analysis ( P  =<I>   0.010); however, the effect of GSS was no longer statistically significant after adjusting for pre-switch clinical (CD4 count and plasma viral load) and demographic variables. Furthermore, only a lower pre-switch CD4 count was associated with increased CD4 recovery in the ‘suppression–1 year’ period in both unadjusted and adjusted models. The main CD4 recovery occurred in ‘switch–suppression’ and the variables associated, both unadjusted and adjusted, were CD4 and plasma viral load at switch, maintaining a trend for GSS ( P  =<I>   0.06). Conclusions: In individuals who re-suppressed HIV viraemia after switching therapy, regimens having a higher GSS were associated with improved CD4 recovery only during the period from switch to virological suppression, but, once viral load is re-suppressed, the GSS of the new regimen has no further effect on subsequent CD4 recovery.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기